12
Participants
Start Date
January 12, 2022
Primary Completion Date
January 30, 2022
Study Completion Date
January 6, 2023
ricolinostat
"This study is an open-label, single-dose phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.~12 subjects are planned to be enrolled, both male and female, and all will receive the investigational drug.~This study includes the screening period, baseline period, dosing/observation period, discharge and follow-up period."
Bethune First Hospital Of Jilin University, Changchun
Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
INDUSTRY